Touchlight announces collaboration with Janssen Biotech
Hampton, London, United Kingdom, 23rd October 2018
Touchlight Genetics Ltd., a biotechnology company developing a novel, synthetic DNA vector platform known as “doggybone” DNA, announced a collaboration with Janssen Biotech, Inc. to evaluate the application of doggybone DNA in the development of multiple genetic therapies, in the fields of infectious disease and oncology. The agreement was facilitated by Johnson & Johnson Innovation Limited.
Under the terms of the agreement, Touchlight will receive research funding to deploy its technology toward two Janssen programs. Janssen and Touchlight will together evaluate and optimise the Touchlight patented DNA vector technology, “doggybone” or dbDNA™ in support of these programs. Financial terms of the agreement were not disclosed.
“This is a great opportunity for Touchlight to further build the evidence base for the advantages of its novel DNA platform across a wide range of applications in genetic medicine” said Dr. Clive Dix, Touchlight’s Chairman.
“Touchlight is delighted to be working with Janssen,” said Jonny Ohlson, Founder and CEO of Touchlight. “Touchlight was founded on the vision that innovative technologies were required to realise the vision of genetic medicine. The collaboration with Janssen is an exciting opportunity for Touchlight to exemplify its revolutionary synthetic DNA platform together with a global leader in biopharmaceuticals”
- ENDS -
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Jonny Ohlson, CEO||Tim Watson / Agnes Stephens /|
|Tommy Duncan, CBO||Katie Duffell|
|E: email@example.com||E: firstname.lastname@example.org|
|T: +44 20 8481 9200||T: +44 20 7457 2020|